Results 21 to 30 of about 51,116 (225)

Study of the possible effect of sacubitril/valsartan combination versus valsartan on the cognitive function in Alzheimer’s disease model in rats

International Journal of Immunopathology and Pharmacology, 2023
Objectives: Alzheimer’s disease (AD) is an irreversible, progressive neurodegenerative disorder. The proportion of elderly individuals at risk for AD and cardiovascular problems increases by raising life expectancy.
Abdallah Salah El-Din Hussein, Rahma Kamal El-Din Abou-El Nour, O. Khorshid, A. Osman   +3 more
semanticscholar   +1 more source

Sacubitril–valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction

European Heart Journal, 2021
Aims Patients with heart failure and preserved ejection fraction (HFpEF) frequently have difficult-to-control hypertension. We examined the effect of neprilysin inhibition on ‘apparent resistant hypertension’ in patients with HFpEF in the PARAGON-HF ...
A. Jackson, P. Jhund, I. Anand, H. Düngen, C. Lam, M. Lefkowitz, G. Linssen, L. Lund, A. Maggioni, M. Pfeffer, J. Rouleau, J. Saraiva, M. Senni, O. Vardeny, M. Wijkman, M. Yılmaz, Yoshihiko Saito, M. Zile, S. Solomon, J. McMurray   +19 more
semanticscholar   +1 more source

Efficacy of sacubitril/valsartan versus olmesartan in Japanese patients with essential hypertension: a randomized, double-blind, multicenter study

Hypertension Research, 2022
This phase III study assessed the efficacy and safety of sacubitril/valsartan compared with those of olmesartan in Japanese patients with essential hypertension.
H. Rakugi, K. Kario, M. Yamaguchi, Takayoshi Sasajima, Hiromi Gotou, J. Zhang   +5 more
semanticscholar   +1 more source

Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction.

Journal of the American Medical Association (JAMA), 2019
Importance In patients with heart failure and reduced ejection fraction (HFrEF), treatment with sacubitril-valsartan reduces N-terminal pro-b-type natriuretic peptide (NT-proBNP) concentrations. The effect of sacubitril-valsartan on cardiac remodeling is
MD JamesL.JanuzziJr, PhD MargaretF.Prescott, Mdmphmba JavedButler, Mdmhs G.MichaelFelker, MD AlanS.Maisel, KevinMcCague, PhD AlexanderCamacho, Mdmph IleanaL.Piña, MD RicardoA.Rocha, Mdmph AmilM.Shah, PharmD KristinM.Williamson, MD ScottD.Solomon, PrescottButler Felker Januzzi, Pina Maisel, S. Rocha, McCague, Camacho, Camacho McCague, CamachoRocha Williamson Butler, ButlerFelker Prescott, Rocha Maisel, S. Williamson   +21 more
semanticscholar   +1 more source

Sacubitril/Valsartan and Frailty in Patients With Heart Failure and Preserved Ejection Fraction.

Journal of the American College of Cardiology, 2022
BACKGROUND Frailty is an increasingly common problem, and frail patients are less likely to receive new pharmacologic therapies because the risk-benefit profile is perceived to be less favorable than in nonfrail patients.
J. Butt, P. Dewan, P. Jhund, I. Anand, D. Atar, Junbo Ge, Akshay S. Desai, L. E. Echeverría, L. Køber, Carolyn S. P. Lam, A. Maggioni, F. Martinez, M. Packer, J. Rouleau, D. Sim, D. V. van Veldhuisen, B. Vrtovec, F. Zannad, M. Zile, J. Gong, M. Lefkowitz, A. Rizkala, S. Solomon, J. McMurray   +23 more
semanticscholar   +1 more source

Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure

Circulation, 2019
Supplemental Digital Content is available in the text. Background: While disease-modifying therapies exist for heart failure (HF) with reduced left ventricular ejection fraction (LVEF), few options are available for patients in the higher range of LVEF (>
S. Solomon, M. Vaduganathan, Brian L. Claggett, M. Packer, M. Zile, K. Swedberg, J. Rouleau, Marc A. Pfeffer, Akshay S. Desai, L. H. Lund, L. Køber, I. Anand, N. Sweitzer, G. Linssen, B. Merkely, Juan Luis Arango, D. Vinereanu, Chen-Huan Chen, M. Senni, A. Sibulo, S. Boytsov, V. Shi, A. Rizkala, M. Lefkowitz, J. McMurray   +24 more
semanticscholar   +1 more source

Sacubitril/Valsartan in Patients With Heart Failure and Concomitant End‐Stage Kidney Disease

Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease, 2022
Background Heart failure with reduced ejection fraction (HFrEF) is a chronic disease with substantial mortality. Management of HFrEF has seen significant breakthrough after the launch of neprilysin inhibitor.
Chih-Yuan Niu, Shang-Feng Yang, Shuo-Ming Ou, Cheng-hsueh Wu, Po‐Hsun Huang, C. Hung, Chih-Ching Lin, Szu-yuan Li   +7 more
semanticscholar   +1 more source

Reverse Remodeling Assessed by Left Atrial and Ventricular Strain Reflects Treatment Response to Sacubitril/Valsartan.

JACC Cardiovascular Imaging, 2022
BACKGROUND The left ventricular global longitudinal strain (LVGLS) and left atrial reservoir strain (LARS) are considered as sensitive and reliable markers of cardiac remodeling and function.
Mi-Gil Moon, In-Chang Hwang, Hyun-Jung Lee, Sun-Hwa Kim, Y. Yoon, Jun‐Bean Park, Seung‐Pyo Lee, Hyung‐Kwan Kim, Yong‐Jin Kim, G. Cho   +9 more
semanticscholar   +1 more source

Impact of Sacubitril/Valsartan Compared With Ramipril on Cardiac Structure and Function After Acute Myocardial Infarction: The PARADISE-MI Echocardiographic Substudy

Circulation, 2022
Background: Angiotensin-converting enzyme inhibitors attenuate left ventricular (LV) enlargement after acute myocardial infarction (AMI). Preclinical data suggest similar benefits with combined angiotensin receptor neprilysin inhibition, but human data ...
A. Shah, B. Claggett, N. Prasad, Guichu Li, Mayra Volquez, K. Jering, M. Čikeš, A. Kovács, W. Mullens, J. Nicolau, L. Køber, P. van der Meer, P. Jhund, G. Ibram, M. Lefkowitz, Yinong Zhou, S. Solomon, M. Pfeffer   +17 more
semanticscholar   +1 more source

Myocardial Perfusion Defects in Hypertrophic Cardiomyopathy Mutation Carriers

Journal of the American Heart Association, EarlyView., 2021
Background Impaired myocardial blood flow (MBF) in the absence of epicardial coronary disease is a feature of hypertrophic cardiomyopathy (HCM). Although most evident in hypertrophied or scarred segments, reduced MBF can occur in apparently normal segments.
Rebecca K. Hughes, Claudia Camaioni, João B. Augusto, Kristopher Knott, Ellie Quinn, Gabriella Captur, Andreas Seraphim, George Joy, Petros Syrris, Perry M. Elliott, Saidi Mohiddin, Peter Kellman, Hui Xue, Luis R. Lopes, James C. Moon   +14 more
wiley   +1 more source